Article
STAT1-Induced HLA Class I Upregulation Enhances Immunogenicity and Clinical Response to Anti-EGFR mAb Cetuximab Therapy in HNC Patients.
Cancer immunology research - 1 Aug 2015
Srivastava Raghvendra M, Trivedi Sumita, Concha-Benavente Fernando, Hyun-Bae Jie, Wang Lin, Seethala Raja R, Branstetter Barton F, Ferrone Soldano, Ferris Robert L
Abstract excerpt
The goal of this study was to characterize the molecular mechanisms underlying cetuximab-mediated upregulation of HLA class I antigen-processing machinery components in head and neck cancer (HNC) cells and to determine the clinical significance of these changes in cetuximab-treated HNC patients. Flow cytometry, signaling studies, and chromatin immunoprecipitation (ChIP) assays were performed using HNC cells...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
